<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TINIDAZOLE</span><br/>(tin'i-da-zole)<br/><span class="topboxtradename">Tindamax<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">azole antibiotic</span>; <span class="classification">antiprotozoal</span>; <span class="classification">amebicide</span><br/><b>Prototype: </b>Metronidazole<br/><b>Pregnancy Category: </b>First trimester D, second and third trimesters C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg, 500 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Made from cell extracts of <i>Trichomonas</i>. The free radicals generated as a result of this process may be responsible for its antiprotozoal activity; however, the
         mechanism of action is unknown.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Demonstrates activity against infections caused by the following protozoa: <i>Trichomonas vaginalis</i>, <i>Giardia duodenalis</i> (also termed <i>G. lamblia</i>), and <i>Entamoeba histolytica</i>.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of trichomoniasis, giardiasis, amebiasis, and amebic liver abscess.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>First trimester of pregnancy (category D), second and third trimesters pregnancy (category C); known hypersensitivity to tinidazole
         or other azole antibiotics (e.g., metronidazole); lactation within 72 h of tinidazole use; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>CNS diseases, liver dysfunction, alcoholism, ethanol intoxication; hematologic disease; neurologic disease; bone marrow depression;
         dialysis; candidiasis.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Giardiasis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2 g as single dose with food<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <img src="../images/special/greaterorequal.gif"/><i>3 y</i> 50 mg/kg (up to 2 g) as single dose with food<br/><br/><span class="indicationtitle">Intestinal Amebiasis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2 g once daily for 3 d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <img src="../images/special/greaterorequal.gif"/><i>3 y</i> 50 mg/kg/d (up to 2 g/d) once daily for 3 d<br/><br/><span class="indicationtitle">Amebic Liver Abscess</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2 g once daily for 35 d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <img src="../images/special/greaterorequal.gif"/><i>3 y</i> 50 mg/kg/d (up to 2 g/d) once daily for 35 d<br/><br/><span class="indicationtitle">Trichomoniasis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2 g as single dose<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food to minimize GI distress; may be crushed in artificial cherry syrup if tablets cannot be swallowed whole.</li>
<li>If given on a dialysis day, add a 50% dose of tinidazole at the end of hemodialysis.</li>
<li>Separate the dosing of cholestyramine and tinidazole by 24 h when used concurrently.</li>
<li>Do not give within 2 wk of the last dose of disulfiram.</li>
<li>Store at 15°30° C (59°86° F). Protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Weakness, fatigue, malaise. <span class="typehead">CNS<b></b>
         			:</span> Dizziness, headache. <span class="typehead">GI<b></b>
         			:</span> Metallic/bitter taste, nausea, anorexia, dyspepsia, cramps, epigastric discomfort, vomiting, constipation. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug<b></b>
         			:</span> May increase INR with <b>warfarin; alcohol</b> may cause abdominal cramps, nausea, vomiting, headache, flushing; psychotic reactions with <b>disulfiram</b>
<b>;</b> may increase the half-life of <b>fosphenytoin, phenytoin</b>
<b>;</b> may increase levels and toxicity of <b>lithium, fluorouracil, cyclosporine, tacrolimus; cholestyramine</b> may decrease absorption of tinidazole. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Peak<b></b>
         			:</span>  2 h. <span class="typehead">Distribution<b></b>
         			:</span> Crosses bloodbrain barrier, placenta and is excreted in breast milk. <span class="typehead">Metabolism<b></b>
         			:</span> Metabolized in the liver by CYP3A4. <span class="typehead">Elimination<b></b>
         			:</span> Primarily excreted in urine. <span class="typehead">Half-Life:</span> 1214 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Withhold drug and notify physician for S&amp;S of CNS dysfunction (e.g., seizures, numbness or paresthesia of extremities). Drug
            should be discontinued if abnormal neurologic signs appear.
         </li>
<li>Lab tests: baseline LTFs; CBC with differential, if retreatment is required.</li>
<li>Monitor INR/PT frequently with concomitant oral anticoagulants. Continue monitoring for at least 8 d after discontinuation
            of tinidazole.
         </li>
<li>Monitor serum lithium levels with concurrent use.</li>
<li>Monitor for phenytoin toxicity with concurrent IV phenytoin.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Stop taking the drug and report promptly: convulsions, numbness, tingling, pain, or weakness in the hands or feet; dizziness
            or unsteadiness; fever.
         </li>
<li>Harmless urine discoloration may occur while taking this drug.</li>
<li>Do not breast feed while taking this drug. Wait at least 3 d after the last dose to resume breast-feeding.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>